Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.30 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.30 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.30 |
| ▸ | SCN1A | P35498 | 1/20 | 0.30 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.30 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29358193 | 1.00 | CA1 (0.38) | CA1CA2CA7CA9HDAC4 | |
| SCHEMBL29639554 | 0.99 | CA1 (0.38) | CA1CA2CA7CA9HDAC4 | |
| SCHEMBL19469294 | 0.96 | CA1 (0.36) | CA1CA2CA7CA9HDAC4 | |
| SCHEMBL12929986 | 0.91 | POLB (0.36) | CA1CA2CA7CA9HDAC4 | |
| SCHEMBL29355132 | 0.91 | POLB (0.36) | CA1CA2CA7CA9HDAC4 | |
| SCHEMBL28859005 | 0.89 | POLB (0.35) | CA1CA2CA7CA9HDAC4 | |
| SCHEMBL30966657 | 0.89 | POLB (0.35) | CA1CA2CA7CA9HDAC4 | |
| Trifluoromethanesulfonic Acid SCHEMBL30107006 | 0.88 | CA1 (0.36) | CA1CA2CA7CA9ALDH1A1 | |
| SCHEMBL20346570 | 0.86 | CA1 (0.33) | CA1CA2CA7CA9 | |
| SCHEMBL28513987 | 0.82 | ALDH1A1 (0.34) | CA1CA2CA7CA9ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1137 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119731143-A | Process for the preparation of biobased olefins from primary alcohols | 巴斯夫欧洲公司 | 2025-03-28 | — | — | CN | claimed |
| US-12233402-B2 | Cross-coupling reaction catalysts, and methods of making and using same | YALE UNIVERSITY (US) | 2025-02-25 | — | — | US | claimed |
| US-20250002519-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | UNIV YALE (US) | 2025-01-02 | — | — | US | claimed |
| US-12162829-B2 | Gas phase process for acrylate production from ethylene and carbon dioxide | CHEVRON PHILLIPS CHEMICAL COMPANY LP (US) | 2024-12-10 | — | — | US | claimed |
| US-12122788-B2 | Process of making CFTR modulators | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2024-10-22 | — | — | US | claimed |
| US-20240326030-A1 | PALLADIUM COMPLEX AND CATALYST EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | UVIC INDUSTRY PARTNERSHIPS INC. (CA) | 2024-10-03 | — | — | US | claimed |
| US-20240300922-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2024-09-12 | — | — | US | claimed |
| US-12071445-B2 | Precatalyst scaffolds for cross-coupling reactions, and methods of making and using same | YALE UNIVERSITY (US) | 2024-08-27 | — | — | US | claimed |
| EP-4359401-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | Blueprint Medicines Corporation (US) | 2024-05-01 | — | — | EP | claimed |
| CN-112469690-B | Method for producing arylamines | 默克专利有限公司 | 2024-04-16 | — | — | CN | claimed |
| CN-108484577-A | A kind of pyrimidine-quinolones heterocomplex and its preparation method and application | 复旦大学 | 2018-09-04 | — | — | CN | claimed |
| EP-2887941-B1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE IRELAND UNLIMITED CO (IE) | 2018-07-11 | — | — | EP | claimed |
| US-20170305948-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | UNIV YALE (US) | 2017-10-26 | — | — | US | claimed |
| EP-3204395-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | Yale University (US) | 2017-08-16 | — | — | EP | claimed |
| EP-2593439-B1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE BAHAMAS LTD (BS) | 2016-08-17 | — | — | EP | claimed |
| WO-2016057600-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | YALE UNIVERSITY (US) | 2016-04-14 | — | — | WO | claimed |
| US-9255074-B2 | Process for preparing antiviral compounds | ABBVIE INC. (US) | 2016-02-09 | — | — | US | claimed |
| US-9233922-B2 | Process for producing N-(hetero)arylazoles | TAKASAGO INTERNATIONAL CORPORATION (JP) | 2016-01-12 | — | — | US | claimed |
| US-8895737-B2 | Process for preparing antiviral compounds | ABBVIE INC. | 2014-11-25 | — | — | US | claimed |
| US-20130224149-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | ABBVIE INC. (US) | 2013-08-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130224149-A1 | PROCESS FOR PREPARING ANTIVIRAL COMPOUNDS | HAVCR2, RNASE1, MAVS | CA1 4130/4885CA2 4346/4885CA7 3225/4885 |
| US-20250002519-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | TIMCC, YAP1, TET2 | CA1 44/4885CA2 93/4885CA7 72/4885 |
| US-12162829-B2 | Gas phase process for acrylate production from ethylene and carbon dioxide | MSMO1, ALOX15, ALOX12 | CA1 2190/4885CA2 1121/4885CA7 473/4885 |
| US-20240326030-A1 | PALLADIUM COMPLEX AND CATALYST EMBODIMENTS AND METHODS OF MAKING AND USING THE SAME | PDCD6IP, PDPK1, PDCD10 | CA1 1318/4885CA2 1046/4885CA7 1476/4885 |
| US-20240300922-A1 | PROCESS FOR PREPARING EGFR INHIBITORS | EGFR, ERBB2, ERBB4 | CA1 3166/4885CA2 1258/4885CA7 1032/4885 |
| US-12122788-B2 | Process of making CFTR modulators | CFTR, SLC26A4, TMEM109 | CA1 4856/4885CA2 2605/4885CA7 4060/4885 |
| US-20170305948-A1 | NOVEL PRECATALYST SCAFFOLDS FOR CROSS-COUPLING REACTIONS, AND METHODS OF MAKING AND USING SAME | TIMCC, YAP1, TET2 | CA1 44/4885CA2 93/4885CA7 72/4885 |
| US-12233402-B2 | Cross-coupling reaction catalysts, and methods of making and using same | TET2, TIMCC, MDM4 | CA1 21/4885CA2 30/4885CA7 31/4885 |
| US-12071445-B2 | Precatalyst scaffolds for cross-coupling reactions, and methods of making and using same | TIMCC, YAP1, TET2 | CA1 44/4885CA2 108/4885CA7 48/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.